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848Objective:Minimally invasive epicardial ablationvia rightminithoracotomy is anemergingoption for patientswith
drug-refractory nonvalvular atrial fibrillation. To guide the development of rational treatment algorithms, factors
predisposing to recurrence of arrhythmia need to be quantified and eventually treated.We addressed the association
of the plasma levels of homocysteine and the recurrence of atrial fibrillation after minimally invasive ablation.
Methods: We obtained peripheral blood samples from 104 patients at follow-up after arrhythmia surgery; the
homocysteine concentration was expressed as micromoles per liter. Prospective follow-up was conducted
through electrocardiogram Holter monitoring (average 18.5  5.8 months). Stratified analysis (high vs low ho-
mocysteine) was based on the cutoff value for the last quartile of homocysteine concentration (16 mmol/L).
Time-to-event and diagnostic performance analyses were performed.
Results: The rate of freedom from atrial fibrillation was 89.4% at the end of follow-up. Elevated circulating
homocysteine level, persistent type of atrial fibrillation, and increased left atrial dimension independently pre-
dicted the recurrence of atrial fibrillation during the follow-up (adjusted Cox regression). Patients with a high
homocysteine level were more likely to have atrial fibrillation recurrence (stratified Kaplan–Meier, P<.001).
The cutoff value for elevated homocysteine (16 mmol/L) yielded a good diagnostic performance in the prediction
of atrial fibrillation recurrence (area under the receiver operating characteristic curve, 0.807).
Conclusions: The homocysteine levelmeasured during the follow-up reliably predicts the risk of recurrence after
epicardial ablation of nonvalvular atrial fibrillation via minithoracotomy. Specific treatments to reduce plasma
homocysteine could be considered in the future in these patients. (J Thorac Cardiovasc Surg 2013;146:848-53)The epicardial off-pump ablation via minithoracotomy is an
emerging option for the treatment of patients affected by
nonvalvular atrial fibrillation (AF). This approach has
been reported to yield superior results in terms of freedom
from arrhythmia compared with the established catheter ab-
lation.1,2 Several factors have been indicated to predict the
recurrence of AF during the postoperative follow-up (in-
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The Journal of Thoracic and Cardiovascular Surgbut the criteria to indicate minimally invasive epicardial ab-
lation for nonvalvular AF need to be refined. We aimed to
ascertain whether the plasma levels of homocysteine
(Hcy), a marker of cardiovascular risk,3,4 may predict the
recurrence of AF. We also aimed to clarify whether Hcy
may work as an additional tool to stratify the risk of
recurrence and, therefore, the clinical cost/benefit ratio
of minimally invasive epicardial ablation in individual
patients.MATERIALS AND METHODS
Patients Selection
Starting in June 2008, we selected patients for minimally invasive abla-
tion of nonvalvular AF according to the following criteria: (1) episodes of
paroxysmal or persistent nonvalvular AF, refractory to the maximal toler-
ated doses of class IC and class III antiarrhythmic drugs, alone or in com-
bination; (2) at least 1 failed direct-current or pharmacologic cardioversion
during the previous 6 months. Patients had to be free from any other cardiac
dysfunction on the basis of the review of recent transthoracic echocardio-
gram and stress electrocardiogram (ECG) tracings. The coexistence of any
valvulopathy graded more than mild and left ventricular ejection fraction
less than 55% was considered exclusion criterion. Paroxysmal AF was de-
fined as episodes of AF lasting less than 7 days and self-terminating,
whereas persistent AF was defined as AF episodes lasting more than 7
days and requiring termination by direct-current or pharmacologicery c October 2013
Abbreviations and Acronyms
AF ¼ atrial fibrillation
AUC ¼ area under the curve
ECG ¼ electrocardiogram
Hcy ¼ homocysteine
RF ¼ radiofrequency
ROC ¼ receiver operating characteristic
TIA ¼ transient ischemic attack
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dimension not exceeding 35 mm/m2 of body surface area. The surgical
evaluation and the enrollment of patients for surgery were collegially per-
formed by cardiac surgeons and electrophysiology cardiologists, and in
compliance with the current guidelines.6
End Points
The end points were (1) effects of the plasma Hcy concentration on the
rate of maintenance of sinus rhythm after minimally invasive ablation of
nonvalvular AF and (2) validation of a cutoff value of plasma Hcy as
a tool to stratify the likelihood of long-term success of minimally invasive
ablation of nonvalvular AF.
Surgery
The surgical technique has been described in detail.7 Briefly, the proce-
dure is conducted via a right minithoracotomy (4 cm) at the third intercostal
space. Videoscopic view and long-shafted instruments are used.After enter-
ing the pericardium, the ablation probe is advanced into the transverse sinus
and the oblique sinus using a dedicated introducer to embrace the left atrium
around the origin of the 4 pulmonary veins. The device uses radiofrequency
(RF) energy and is suction-assisted to optimize the contact with themyocar-
dium (Cobra Adhere XL Surgical System; Estech Inc, San Ramon, Calif).
RF energy is delivered to obtain a midwall temperature of 80C and
electrical isolation of the pulmonary veins (circular box lesion). This lesion
set was uniformly applied to all the study patients. All procedures were per-
formed by 2 surgeons (G.N. and G.S.) using established protocols. Two
energy applications lasting 150 seconds each were delivered, followed by
a 60-second application after the probe was moved circumferentially, to
achieve complete closure of the box lesion. Conduction block was verified
by pacing of the pulmonary veins (exit block). Complete block was consid-
ered to be indicative of effective electrical isolation. When feasible, the
patients were extubated in the operative room. The operation is completely
off-pump. After discharge from the intensive care unit, electrical cardiover-
sion was performed whenever required. For the purposes of the present
analysis, we defined as recurrence any episode of AF that could be demon-
strated at any time during the follow-up, after hospital discharge.
Study Measurements, Follow-up, and Collection of
Data
Since the introduction of minimally invasive epicardial RF ablation at
our Anthea Hospital, GVM Care & Research (Bari, Italy), all clinical
data pertaining to the patients undergoing this procedure are prospectively
collected and included in an electronic database. The dataset includes base-
line characteristics, intraoperative and postoperative results, and follow-up
data. The variables were defined and collected according to the current ded-
icated guidelines.8 The preoperative evaluation included the calculation of
the Congestive heart failure, Hypertension, Age 75, Diabetes mellitus,
and prior Stroke or transient ischemic attack score (CHADS), which has
been validated for the establishment of the most adequate level of antico-
agulation therapy on the basis of the predicted risk of stroke in patientsThe Journal of Thoracic and Cawith nonrheumatic AF.9 The database was filled in at the time of the dis-
charge of each patient from the hospital and was periodically checked
for errors and omissions. After hospital discharge, patients were followed
up by scheduled visits at 3 and 6 months, and every 6 months thereafter to
determine the rate of AF recurrence. Visits included physical examination,
review of 24-hour Holter ECG tracings, and transthoracic echocardiogra-
phy. Echocardiography included pulsed-Doppler examination to assess
the presence of atrial transport function (defined as evidence of filling A
wave with a peak flow velocity of 0.4 m/sec or more). This had to be cou-
pled to the ECG tracing to define the absence of AF recurrence. Telephone
contacts were performed on a monthly basis. Unscheduled visits and
24-hour Holter ECG examinations were performed whenever symptoms
suggestive of arrhythmia relapse were reported by the patients. The study
subjects remained on an antiarrhythmic drug regimen until stable sinus
rhythm was demonstrated at both the 3-month and the 6-month follow-
up time points. Anticoagulation therapy was withdrawn when stable sinus
rhythm was demonstrated up to 9 months after surgery. With respect to
time-to-event analysis, prospective event recording (recurrence of AF)
was initiated from the day of hospital discharge.
In all patients, a sample of serumwas taken from a peripheral vein at the
time of the sixth postoperative month follow-up visit. Samples were imme-
diately processed to determine the plasma level of Hcy using a commer-
cially available kit (Mitsubishi Chemical Medience Corp, Tokyo, Japan).
Hcy levels were expressed as micromoles per liter. Subsequently, the pa-
tients were assigned to 2 groups according to a cutoff value for the last
quartile of plasma Hcy concentration in our population (16 mmol/L). Pa-
tients with plasma Hcy 16 mmol/L or greater were included in the high
Hcy group, and patients with plasma Hcy less than 16 mmol/L were in-
cluded in the lowHcy group. Suchmethodology is consistent with previous
reports in the literature.3,10,11 Enlarged left atrial size was defined as
a maximum diameter of the left atrium exceeding 22 mm/m2 of body
surface area in the apical 4-chamber echocardiographic view. All of the
measurements were performed using the same echocardiography apparatus
in consensus by 2 skilled cardiologists. The local ethical committee ap-
proved the study protocol, and the patients provided informed consent to
enter the study and to the management of data.Statistical Analysis
Continuous data are presented as mean  standard deviation, and cate-
goric variables are presented as percentages. Intergroup comparison was
performed using the Student t test (continuous variables) and the chi-
square test (categoric variables). All tests were 2-tailed. Multiple logistic
regression was used to identify the predictors for the need of predischarge
electrical cardioversion.Multivariable Cox proportional hazards regression
was performed to identify the predictors of AF recurrence during the
follow-up. All of the available patients’ data were included as potential ex-
planatory variables. The assumptions of both regression models were
checked and met. All of the variables available in each patient’s dataset
were entered in the models as potential explanatory variables, including
the Hcy level, baseline characteristics (demographics, type and duration
of AF, type of preoperative antiarrhythmic therapy, left atrial dimension,
New York Heart Association functional class, left ventricular dimension,
and ejection fraction), and intraoperative variables (type of ablation pat-
tern, need for early postoperative cardioversion). Left atrial diameter was
managed as a dichotomous variable (enlarged vs nonenlarged left atrium).
The Kaplan–Meier method was used to build the curves for recurrent AF-
free survival during the follow-up. Stratified analysis according to the high
Hcy versus low Hcy group was performed, and the corresponding curves
were analyzed using the log-rank statistic. The diagnostic performance
of serum Hcy cutoff value in predicting the recurrence of AF at any time
during the follow-up was evaluated by construction of receiver operating
characteristic (ROC) curves. The area under the curve (AUC) was quanti-
fied according to a parametric methodology (because it is best suited for
smaller samples) and adopted as a measure of diagnostic accuracy.rdiovascular Surgery c Volume 146, Number 4 849
TABLE 2. Variable-based comparison of the high homocysteine group
versus the low homocysteine group
High Hcy group Low Hcy group
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ley andMcNeil statistic (MedCalc software,Mariakerke, Belgium). The al-
pha level was 0.05. The analyses were conducted using the Statistical
Package for the Social Sciences version 13.0 (SPSS, Inc, Chicago, Ill).
Characteristic N ¼ 28 N ¼ 76 P
Previous stroke/TIA 7 (25%) 2 (2.6%) <.001
Duration of AF (y) 3.4  1.5 3.1  1.4 .21
Postoperative cardioversion 8 (88.9%) 17 (40.5%) .022
Inclusion into subgroups was based on the cutoff valve of Hcy (16 mmol/L). TIA,
Transient ischemic attack; AF, atrial fibrillation.RESULTS
A total of 104 patients were treated with minimally inva-
sive epicardial ablation for nonvalvular AF. Table 1 summa-
rizes the main baseline features of these patients. There
were no cases of operativemortality and 3 cases of perioper-
ative morbidity (2.9%; 1 case of intraoperative bleeding, 2
cases of stroke/transient ischemic attack [TIA]). Twenty pa-
tients (19.2%) required cardioversion before discharge be-
cause of AF/supraventricular tachycardia. All patients but 1
were discharged in sinus rhythm. Multiple logistic
regression identified persistent type of AF (odds ratio,
6.57; P< .001) and increased Hcy level (odds ratio, 2.7;
P ¼ .0021) as factors independently associated with the
need of predischarge cardioversion.
During the follow-up (average duration, 18.5  5.8
months), 11 clinical relapses of AF were recorded (freedom
from AF, 90.4% at 6 months and 89.4% at 12 months). In
the present series, there were no patients presenting sinus
rhythm on ECG tracings and absence of atrial transport
function on pulsed Doppler. The rate of recurrence of AF
was 5.9% among the patients with paroxysmal AF versus
15.1% among the patients with persisting AF. There were
no thromboembolic events during the follow-up; 2 patients
died of noncardiac causes. In the overall population, we re-
corded a higher mean Hcy level among patients who later
had arrhythmia recurrence during the follow-up (18.6 
4.7 mmol/L) compared with patients who remained in stable
sinus rhythm (13.5  5.9 mmol/L). The difference wasTABLE 1. Baseline characteristics of the study population
Characteristic
Age (y) 63.9  8
Sex (male/female) 39/65
Left atrial dimension (mm) 41.9  5
Left ventricular ejection fraction (%) 58.1  2.8
Diabetes mellitus (n,%) 21 (20.2%)
Hypertension (n,%) 54 (51.9%)
Creatinine (mg/dL) 0.9  0.3
Previous transcatheter ablation (n,%) 24 (23.1%)
Previous stroke/TIA 9 (8.6%)
Duration of AF (y) 2.6  1.4
Paroxysmal-to-resisting AF ratio 49%-51%
CHADS score
CHADS 0 29 (27.9%)
CHADS 1 50 (48.1%)
CHADS 2 17 (16.3%)
CHADS 3 8 (7.7%)
TIA, Transient ischemic attack; AF, atrial fibrillation; CHADS, Congestive heart fail-
ure, Hypertension, Age75, Diabetes mellitus, and prior Stroke or transient ischemic
attack.
850 The Journal of Thoracic and Cardiovascular Surgstatistically significant (P ¼ .007). In addition, patients
with an enlarged left atrium had a significantly higher
mean Hcy level than patients with a normal left atrial di-
mension (P < .01). Likewise, patients with paroxysmal
AF demonstrated a 12.9  6.2 mmol/L Hcy concentration
versus 15.3  5.6 mmol/L in patients with persistent AF
(P ¼ .043). After dividing the patients into 2 strata accord-
ing to the circulating Hcy level, it emerged that the patients
included in the high Hcy subgroup were characterized by
a statistically higher rate of previous cerebrovascular event
(stroke or TIA) and of need of postoperative cardioversion.
The average duration of AF was not statistically different
among groups (Table 2). Twenty-eight patients (26.9% of
the overall population) entered the high Hcy group accord-
ing to the described criteria. Eighteen of these patients
(64.3%) had required early postoperative cardioversion be-
fore hospital discharge because of AF or supraventricular
tachycardia immediately after the intensive care unit stay.
These represented the 90% of the patients who required
early cardioversion in the entire study population; the dif-
ference versus patients who were included in the low Hcy
group was statistically significant (P< .001). Recurrence
of AF was observed in 9 patients in the high Hcy group
(32%) versus 2 patients in the low Hcy group (2.6%)
(P<.001). Table 3 shows the stratified incidence of AF re-
currence according to the type of AF (paroxysmal or per-
sisting) and the Hcy level group (high or low). The results
of the Cox proportional hazards regression are shown in
Table 4. An elevated Hcy value is identified as an indepen-
dent predictor of recurrence of AF. Thus, this conclusion is
not biased by the association of elevated Hcy level with both
enlarged left atrium and persistent type of AF, which appear
as the other 2 independent predictors of AF recurrence. Ka-
plan–Meier analysis confirmed that patients with elevatedTABLE 3. Results of Cox proportional hazards regression: Predictors
of recurrence and time to recurrence of atrial fibrillation
Characteristic
Paroxysmal AF
N ¼ 51
Persisting AF
N ¼ 53
High Hcy Low Hcy High Hcy Low Hcy
Recurrence of AF 3 0 6 2
No recurrence AF 8 40 11 34
Hcy, Homocysteine; AF, atrial fibrillation.
ery c October 2013
TABLE 4. Results of Cox proportional hazards regression: Predictors
of recurrence and time to recurrence of atrial fibrillation
Characteristic
Standard
error
Hazard
ratio P
95% hazard ratio
confidence limits
Hcy level (continuous
variable)
0.063 3.1 .0029 2.06-4.55
Elevated Hcy (categoric
variable)
0.051 4.0 <.001 3.2-4.93
Type of AF: persistent 0.074 1.36 .004 0.97-2.05
Left atrial dimension 0.058 3.7 <.001 2.59-4.48
Hcy, Homocysteine; AF, atrial fibrillation.
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rence of AF during the follow-up (log-rank P < .001)
(Figure 1).
In our population, the cutoff value of plasma Hcy ¼ 16
mmol/L, corresponding to the cutoff for the last quartile
for Hcy concentration, yielded a good diagnostic perfor-
mance in predicting the recurrence of AF at any time during
the follow-up (ROC AUC ¼ 0.807) (Figure 2). Such an
AUC value was statistically higher than that obtained for
different potential cutoff values; to such a purpose, we
tested the cutoff for each decile of the distribution of Hcy
in the present population (ROC curves not shown).DISCUSSION
AF, one of the most common cardiac rhythm distur-
bances in adults, is a major determinant of cardiovascular
morbidity and mortality, mainly due to thromboembo-
lism.12 Currently, the rate of failure of medical rhythm-
control strategies may reach 77% at 36 months,13 whereas
the rate of AF recurrence after the second-line treatment
(transcatheter ablation) in patients with drug-refractoryFIGURE 1. Kaplan–Meier curves for recurrent AF-free survival in the overall
The difference between the 2 curves reported in B is statistically significant. *L
The Journal of Thoracic and CaAF may reach 37% even after repeated ablation proce-
dures.14 The traditional Maze treatment offered by cardiac
surgery, despite better success rates and contained morbid-
ity, is limited by its invasiveness and the need for cardiopul-
monary bypass. These latter features make its application
scarcely accepted by the patients affected by nonvalvular
AF. Therefore, a therapeutic gap exists for patients with iso-
lated AF. Notwithstanding, it is currently possible to per-
form an AF ablation surgery on the beating heart and
through a 4-cm minithoracotomy. Such a concept is based
on thoracoscopy-assisted surgery and RF energy delivery
through a dedicated suction-assisted probe to obtain electri-
cal isolation of the pulmonary veins. Such a strategy has
been conceptually validated for nonvalvular AF,15 because
the electrical trigger is located within the pulmonary veins
cuff in the majority of cases of nonvalvular AF.16 Our
previous clinical data indicate that the presented
surgical procedure is safe and that it may yield optimal
recurrence-free survival during the follow-up, but also
that factors such as increased atrial dimension and
persistent type of AF are associated with increased
likelihood of recurrence.2,7 Nonetheless, such elements
are insufficient to prompt rational algorithms for the
indications and contraindications to minimally invasive
ablation of nonvalvular AF.
Evidence is accumulating that circulating Hcy, an amino
acid metabolite of cysteine and methionine, is pathophysio-
logically linked with left atrial enlargement and the likeli-
hood to develop AF (both valvular and nonvalvular AF).17
Hyperhomocysteinemia occurs under the condition of oxi-
dant stress and is the expression of depleted circulating glu-
tathione;18 on the other hand, it is accepted that increased
oxidant stress represents a trigger of atrial myocardialstudy population (A) and the high Hcy group versus the low Hcy group (B).
og-rank P value. Hcy, Homocysteine.
rdiovascular Surgery c Volume 146, Number 4 851
FIGURE 2. ROC curve for the cutoff value of the last quartile of Hcy con-
centration in our population (16 mmol/L) in the prediction of AF recurrence
at any time during the follow-up. AUC, Area under the curve.
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Nonetheless, it is likely that Hcy plays a direct role in the
determinism of atrial myocardial remodeling and in influ-
encing the electrophysiologic milieu toward promotion
and sustainment of AF.20 A direct effect of Hcy on potas-
sium currents of atrial human myocytes may be at the
root of such finding.21 In addition, hyperhomocysteinemia
is associated not only with increased likelihood of develop-
ing AF but also with endothelial dysfunction and higher
stroke risk in patients with persistent AF. Such a concept
was confirmed by the clinical finding that increased Hcy
predicts the recurrence of AF after direct-current cardiover-
sion11 and the occurrence of adverse cardiovascular events
after transcatheter RF ablation of AF.4
The present data are consistent with previous evidence
that hyperhomocysteinemia is associated with enlarged
left atrium and persistent type of AF.4 In addition, we dem-
onstrate that as for patients who have undergone transcath-
eter ablation, elevated Hcy is closely associated with
recurrence of AF during the follow-up after minimally inva-
sive surgical ablation. Such an association is not dependent
on other variables, such as left atrial diameter, type of AF,
and coexistence of hypertension, which may be confound-
ing factors (as indicated by the Cox regression model).
This concept seems to be consistent with the previous find-
ing that the role played by Hcy in the pathophysiology of
cardiovascular disease is independent of interaction with
other pathways.3,10 All of the patients enrolled in our
series consistently were free from any heart disease other
than AF. Elevated Hcy also represents an independent risk
factor for the need for predischarge cardioversion because852 The Journal of Thoracic and Cardiovascular Surgof onset of AF in the perioperative period (logistic
regression), whereas patients demonstrating higher Hcy
levels were more likely to have a history of stroke or TIA.
Collectively, these findings suggest that elevated Hcy can
be regarded as a marker of aggressiveness of the disease
and, consequently, of the likelihood of AF recurrence.
We then hypothesized that the assessment of circulating
Hcy may become part of the evaluation of potential candi-
dates for minimally invasive ablation, and therefore contrib-
ute along with other risk factors for recurrence to the
establishment or refusal of surgical indication. We quanti-
fied the efficacy of a given cutoff of Hcy (test variable) in
predicting the outcome event recurrence of AF during the
follow-up (state variable) by means of formal diagnostic
performance analysis and ROC curves as the plot of test
sensitivity to the false-positive rate. Such an approach facil-
itates the clinical application of the Hcy assessment in clin-
ical judgment. Nonetheless, although in our population we
found that an Hcy concentration of 16 mmol/L displays an
adequate diagnostic performance (area under the ROC,
0.807), other authors have proposed different cutoff values
to this aim,4,11 which suggests the existence of a population
bias and underscores the need for larger and tailored
investigations that also need to take into account the
measurement of preoperative Hcy levels. Nonetheless, no
formal diagnostic performance analyses have been
reported, and we believe that such a conceptual approach
may be extended to the future research in this field.
The present series confirms the efficacy in maintenance
of sinus rhythm at follow-up after minimally invasive surgi-
cal ablation (89.4% freedom from recurrence at the
12-month follow-up) compared with state-of-the art cathe-
ter ablation.4,22 We also confirm the increased rate of AF
recurrence in patients with preoperative persisting AF. We
also underscore that the results of the rate of freedom
from recurrence in the paroxysmal patients treated by
minimally invasive surgical ablation (followed by 6
months of antiarrhythmics) is excellent (5.9% rate of
recurrence). This may prompt a reflection over the
efficacy of alternative treatment strategies (catheter vs
surgical ablation) even in the patients with paroxysmal
AF. Remarkably, the majority of the instances of
recurrence in our series occur in the earliest phase of the
follow-up (91% of cases within the sixth postoperative
month) (Figure 1, A). This supports the stability of results
over time, despite withdrawal of antiarrhythmic drugs at
the sixth postoperative month. Conversely, it is reported
that more than 40% of patients who remain in stable sinus
rhythm within 1 year after transcatheter ablation will later
develop arrhythmia recurrence.22 One recent randomized
trial has suggested that the epicardial surgical ablation
may yield better results than transcatheter ablation in pa-
tients with coexisting risk factors for arrhythmia recur-
rence.1 Under this perspective, the assessment of Hcyery c October 2013
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pected effectiveness of each strategy and understand
whether the more aggressive surgical approach would be
advisable. The analysis of recurrence-free survival was con-
ducted according to the Kaplan–Meier methodology.
Because ultimately the occurrence of AF during the
follow-up is not a definitive outcome event (eg, mortality),
the Kaplan–Meier curves may be theoretically misleading.
Nonetheless, we decided to address the reliability of mini-
mally invasive surgical ablation in achieving complete free-
dom from recurrent AF: therefore, even 1 demonstration of
recurrence during the follow-up marked a definitive out-
come event with respect to our intended purposes, even
though the same patient was in sinus rhythm at 1 subsequent
time point. Nonetheless, all patients in our series who were
in AF at any follow-up time point were found to show AF
even at the subsequent time point(s).
Study Limitations
The present investigation must account for some limita-
tions. The study population is limited (104 patients); none-
theless, the estimates of the regression model excluded
model overfitting. Moreover, only the Hcy level measured
at the sixth postoperative month was available. The mea-
surement of the preoperative Hcy levels would be more use-
ful to help establish the indication for the surgical treatment
of nonvalvular AF. The present study design allows us to
conclude that even the Hcy levels measured during the post-
operative follow-up have a predictive value and may be
used to tailor the pharmacologic treatment and the clinical
surveillance. To definitely clarify the role of Hcy level mea-
surement in the prediction of recurrent AF, additional inves-
tigations focused on the preoperative Hcy level are required
and currently ongoing at our Anthea Hospital, GVMCare &
Research (Bari, Italy).
CONCLUSIONS
Hcy plays a complex role in the pathophysiology of AF.
Although the molecular interplay of Hcy with the atrial
myocardium remains to be clarified, the measurement of
circulating Hcy level may already have a clinical fallout.
This measurement is reliable in stratifying the risk of recur-
rence after RF ablation of nonvalvular AF via a minimally
invasive surgical route, thus opening new avenues of re-
search for the development of novel treatment algorithms
for this arrhythmia. Future treatments aimed at reducing
the Hcy level may be evaluated as a strategy to further im-
prove the surgical results in these patients.
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